The people behind the ideas.
The ideas behind the companies.

Unstructured
Unstructured’s
Brian Raymond
on tackling engineering bottlenecks
Rover
Rover’s
Aaron Easterly
on the love of pets and finding the right partners
Pulumi
Pulumi’s
Joe Duffy
on bringing more power to developers
OctoAI
OctoAI’s
Luis Ceze
on bringing ML to all platforms
Common Room
Common Room’s
Linda Lian
on integrating community into your company
Spotnana
Spotnana’s
Sarosh Waghmar
on challenging a decades-old industry
Statsig
Statsig’s
Vijaye Raji
on using data to build better products
RelationalAI
RelationalAI’s
Molham Aref
on finding investors who believe in your passion
Highspot
Highspot’s
Robert Wahbe
on customers, AI, and building relationships that last
Crowd Cow
Crowd Cow’s
Elizabeth Liu
on the power of e-commerce to transform an industry
Nautilus Bio
Nautilus Bio’s
Sujal Patel and Parag Mallick
on the proteome
SeekOut
SeekOut’s
Anoop Gupta
on hiring and untapped talent pools
Pendulum
Pendulum’s
Mark Listes
on finding hidden narratives in social media
Flexe
Flexe’s
Karl Siebrecht
on transforming the logistics industry

Company List

  • A-Alpha Bio
    A-Alpha Bio uses synthetic biology and machine learning to measure and engineer protein-protein interactions and generate high-resolution models of biology for drug discovery. The company has developed a proprietary platform technology, called AlphaSeq, that uses genetically engineered cells to experimentally measure millions of protein-protein interaction affinities simultaneously at a library-on-library scale, generating enormous amounts of data to inform the discovery and development of the next generation of high-impact therapeutics. A-Alpha Bio was founded in 2017 by a team of synthetic biologists from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
    Initial Investment
    2019
    A-Alpha Bio uses synthetic biology and machine learning to measure and engineer protein-protein interactions and generate high-resolution models of biology for drug discovery. The company has developed a proprietary platform technology, called AlphaSeq, that uses genetically engineered cells to experimentally measure millions of protein-protein interaction affinities simultaneously at a library-on-library scale, generating enormous amounts of data to inform the discovery and development of the next generation of high-impact therapeutics. A-Alpha Bio was founded in 2017 by a team of synthetic biologists from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
    Founders
    David Younger
    Randolph Lopez
    Initial Investment
    2019
  • Modulus Therapeutics
    Modulus Therapeutics is a seed-stage cell therapy design studio developing an internal pipeline of NK cell anti-solid tumor programs. Failures in cell therapy efficacy can be traced to poor conceptualization, design and integration of engineered components. Modulus is uniting whole-cell synthetic biology with machine learning into a cell therapy design solution to dramatically reduce pipeline risk and accelerate the path to the clinic. The team is a diverse group of cell therapy veterans along with bioengineering and machine learning experts laser focused on driving therapeutic efficacy by accessing the full cell design space.
    Initial Investment
    2021
    Modulus Therapeutics is a seed-stage cell therapy design studio developing an internal pipeline of NK cell anti-solid tumor programs. Failures in cell therapy efficacy can be traced to poor conceptualization, design and integration of engineered components. Modulus is uniting whole-cell synthetic biology with machine learning into a cell therapy design solution to dramatically reduce pipeline risk and accelerate the path to the clinic. The team is a diverse group of cell therapy veterans along with bioengineering and machine learning experts laser focused on driving therapeutic efficacy by accessing the full cell design space.
    Founders
    Bryce Daines
    Max Darnell
    Initial Investment
    2021
  • Outbound AI
    Outbound AI is Conversation AI built for healthcare. Founded in 2021, the Seattle-based startup is breaking new ground with cloud technologies that serve as workforce multipliers to drive productivity while improving the daily job experience for human talent. The company’s inaugural offering includes a portfolio of AI-powered virtual agents specially trained to streamline administrative work across the revenue cycle, including claims status, eligibility and benefits verification, prior authorization, and more. Outbound AI is led by a passionate team of health and voice tech veterans and backed by several preeminent venture capital firms.
    Initial Investment
    2021
    Outbound AI is Conversation AI built for healthcare. Founded in 2021, the Seattle-based startup is breaking new ground with cloud technologies that serve as workforce multipliers to drive productivity while improving the daily job experience for human talent. The company’s inaugural offering includes a portfolio of AI-powered virtual agents specially trained to streamline administrative work across the revenue cycle, including claims status, eligibility and benefits verification, prior authorization, and more. Outbound AI is led by a passionate team of health and voice tech veterans and backed by several preeminent venture capital firms.
    Founders
    Stead Burwell
    Jonathan Wiggs
    Kshitij Moghe
    Justin Ith
    Initial Investment
    2021
  • Ozette
    Ozette Technologies, Inc. is engineering a transformative leap in cell discovery and annotation of the human immune system. The Seattle-based (remote-first) life sciences technology startup is building a groundbreaking high-resolution, intelligent, single-cell immune monitoring platform and corpus of high-resolution data leveraging its novel AI technologies. Founded in late 2020, Ozette was spun-out from the Fred Hutchinson Cancer Center and incubated at the Allen Institute for AI. Ozette’s interdisciplinary team is made up of a deep bench of scientists, engineers, and designers with a wide range of experience spanning Genentech, Google, Microsoft, Amazon, Airbnb, and leaders and pioneers in the field of medical research and single cell analysis.
    Initial Investment
    2021
    Ozette Technologies, Inc. is engineering a transformative leap in cell discovery and annotation of the human immune system. The Seattle-based (remote-first) life sciences technology startup is building a groundbreaking high-resolution, intelligent, single-cell immune monitoring platform and corpus of high-resolution data leveraging its novel AI technologies. Founded in late 2020, Ozette was spun-out from the Fred Hutchinson Cancer Center and incubated at the Allen Institute for AI. Ozette’s interdisciplinary team is made up of a deep bench of scientists, engineers, and designers with a wide range of experience spanning Genentech, Google, Microsoft, Amazon, Airbnb, and leaders and pioneers in the field of medical research and single cell analysis.
    Founders
    Ali Ansary
    Greg Finak
    Evan Greene
    Raphael Gottardo
    Initial Investment
    2021
  • Terray
    Terray Therapeutics is an emerging biotechnology company led by pioneers and long-time leaders in AI, medicinal chemistry, biology and preclinical development, automation, and nanotechnology to propel drug discovery into the information age. Terray’s proprietary integrated computational and experimental platforms generate massively scaled, powerfully agnostic chemical data that are purpose-built to power computational learning and reveal new interactions. This foundation is building an iterative, flexible chemistry engine that aims to deliver more precise therapies to patients faster than ever before.
    Initial Investment
    2020
    Terray Therapeutics is an emerging biotechnology company led by pioneers and long-time leaders in AI, medicinal chemistry, biology and preclinical development, automation, and nanotechnology to propel drug discovery into the information age. Terray’s proprietary integrated computational and experimental platforms generate massively scaled, powerfully agnostic chemical data that are purpose-built to power computational learning and reveal new interactions. This foundation is building an iterative, flexible chemistry engine that aims to deliver more precise therapies to patients faster than ever before.
    Founders
    Jacob Berlin
    Eli Berlin
    Initial Investment
    2020